In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Rezolute, with a price target of $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yun Zhong’s rating is based on the promising potential of Rezolute’s lead candidate, ersodetug, which is currently in a Phase 3 trial for congenital hyperinsulinism (cHI). The expectation for positive top-line data from this study is a significant factor, as it addresses a critical unmet medical need in the treatment of cHI.
Additionally, the competitive landscape and the potential market adoption of ersodetug are favorable, suggesting a strong commercial opportunity. The clinical development pathway for Rezolute’s candidate appears robust, and the company’s strategic positioning in the market enhances its prospects for success.
According to TipRanks, Zhong is an analyst with an average return of -10.1% and a 41.77% success rate. Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Rezolute, and Protagonist Therapeutics.
In another report released yesterday, Citizens JMP also maintained a Buy rating on the stock with a $17.00 price target.